<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561768</url>
  </required_header>
  <id_info>
    <org_study_id>NVX 778.S205</org_study_id>
    <nct_id>NCT01561768</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults</brief_title>
  <official_title>A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-64) Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the immune response of three dose levels of the&#xD;
      Novavax Quadrivalent vaccine in healthy young adults (18-64). The study is broken down into 5&#xD;
      treatment groups. Each group will enroll 100 subjects, for a total of 500 subjects. Group 1-3&#xD;
      will receive one of three dose levels of the Novavax Quadrivalent vaccine, Group 4 will&#xD;
      receive a dose of the Novavax Trivalent vaccine, and Group 5 will receive a commercially&#xD;
      available trivalent influenza vaccine (TIV). The study will also evaluate the safety and&#xD;
      tolerability of the Novavax Quadrivalent vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of 3 dose levels of the Novavax Quadrivalent vaccine based on HAI responses</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Solicited and Unsolicited Adverse Events for the Novavax Quadrivalent vaccine</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate capacity of the Novavax Quadrivalent vaccines to fulfill FDA criteria (immunogenicity) for all strains in healthy, young adults</measure>
    <time_frame>Day 21</time_frame>
    <description>Based on criteria of greater than or equal to 40% HAI seroconversion and greater than or equal to 70% of subjects with HAI titers greater than or equal to 1:40 post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of including a fourth strain in the Novavax Quadrivalent vaccine on immune responses to other three strains</measure>
    <time_frame>Day 21</time_frame>
    <description>Based on comparison to a trivalent NovaFlu formulation tested at the 22.5ug of HA (per strain) dose level.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novavax Quadrivalent vaccine</intervention_name>
    <description>Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novavax Quadrivalent vaccine</intervention_name>
    <description>Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novavax Quadrivalent vaccine</intervention_name>
    <description>Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novavax Trivalent vaccine</intervention_name>
    <description>Trivalent Dose; intramuscular injection, deltoid</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cTIV</intervention_name>
    <description>Preconfigured dose; intramuscular injection, deltoid</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male or females, 18-64 years of age&#xD;
&#xD;
          2. Willing and able to give informed consent prior to study enrollment&#xD;
&#xD;
          3. Able to comply with study requirements&#xD;
&#xD;
          4. Women who are not post-menopausal (≥ 50 years of age and at least one year post last&#xD;
             menses) or surgically sterile must have a negative urine pregnancy test at&#xD;
             vaccination; will be advised through the Informed Consent process to avoid becoming&#xD;
             pregnant over the duration of the study, and must assert that they will employ an&#xD;
             effective form of birth control for the duration of the study. Acceptable forms of&#xD;
             birth control are: credible history of abstinence from heterosexual activity, hormonal&#xD;
             contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives&#xD;
             (condom or diaphragm, with spermicide), and intrauterine device (IUD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in research involving investigational product (drug/biologic/device)&#xD;
             within 45 days before planned date of first vaccination&#xD;
&#xD;
          2. History of a serious reaction to prior influenza vaccination, known allergy to&#xD;
             constituents of licensed TIV (e.g., egg proteins) or polysorbate-80&#xD;
&#xD;
          3. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza&#xD;
             vaccine&#xD;
&#xD;
          4. Received any vaccine in the 4 weeks preceding the study vaccination and any influenza&#xD;
             vaccine within six months preceding the study vaccination&#xD;
&#xD;
          5. Any know or suspected immunosuppressive illness, congenital or acquired, based on&#xD;
             medical history and/or physical examination&#xD;
&#xD;
          6. Chronic administration (defined as more than 14 continuous days) of immunosuppressants&#xD;
             or other immune-modifying drugs within 6 months prior to the administration of the&#xD;
             study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a&#xD;
             systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled,&#xD;
             and nasal glucocorticoids will be permitted.&#xD;
&#xD;
          7. Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the study vaccine or during the study&#xD;
&#xD;
          8. Acute disease at the time of enrollment (defined as the presence of a moderate or&#xD;
             severe illness with or without fever, or an oral temperature &gt;38.0°C on the planned&#xD;
             day of vaccine administration)&#xD;
&#xD;
          9. Presence of chronic pulmonary (including asthma), cardiovascular (except&#xD;
             hypertension), renal, hepatic, neurologic, hematologic or metabolic (including&#xD;
             diabetes mellitus) disorders, which would include the potential subject in a&#xD;
             &quot;high-risk&quot; category for influenza and/or its complications&#xD;
&#xD;
         10. Known disturbance of coagulation&#xD;
&#xD;
         11. Women who are breastfeeding or plan to become pregnant during the study&#xD;
&#xD;
         12. Suspicion or recent history (within one year of planned vaccination) of alcohol or&#xD;
             other substance abuse&#xD;
&#xD;
         13. Any condition that in the opinion of the investigator would pose a health risk to the&#xD;
             subject if enrolled or could interfere with evaluation of the vaccine or&#xD;
             interpretation of study results (including neurologic or psychiatric conditions deemed&#xD;
             likely to impair the quality of safety reporting)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Thomas, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Novavax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.novavax.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <disposition_first_submitted>July 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 18, 2013</disposition_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

